Wide Ranks

EDIT

Editas Medicine, Inc.

2.20

Top Statistics
Market Cap 181 M Forward PE -0.9543 Revenue Growth -98.90 %
Current Ratio 3.75 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.2020 Enterprise / Revenue -0.7290 Price To Sales Trailing12 Months 2.94
Profitability
Profit Margins 0.00 % Operating Margins -107649.18 %
Balance Sheet
Total Cash 265 M Total Cash Per Share 3.21 Total Debt 38 M
Total Debt To Equity 21.91 Current Ratio 3.75 Book Value Per Share 2.13
All Measures
Short Ratio 761.00 % Message Board Id finmb_252050056 Shares Short Prior Month 18 M
Return On Equity -0.7856 City Cambridge Uuid 93762d80-2eed-34b3-a1c5-9d1d46b35248
Previous Close 2.21 First Trade Date Epoch Utc 1 B Book Value 2.13
Beta 2.01 Total Debt 38 M Volume 1 M
Price To Book 1.03 Fifty Two Week Low 2.13 Total Cash Per Share 3.21
Total Revenue 61 M Shares Short Previous Month Date 1 B Target Median Price 8.00
Max Age 86400 Recommendation Mean 2.11 Sand P52 Week Change 0.3133
Operating Margins -107649.18 % Target Mean Price 8.21 Net Income To Common -210572000
Short Percent Of Float 0.2440 Implied Shares Outstanding 82 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M Average Volume10days 2 M
Total Cash 265 M Next Fiscal Year End 1 B Revenue Per Share 0.7520
Held Percent Insiders 0.0032 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.21 Target Low Price 1.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.10 Open 2.23
Free Cashflow -113797624 State MA Dividend Yield 0.00 %
Return On Assets -0.3432 Time Zone Short Name EST Trailing Eps -2.54
Day Low 2.18 Address1 11 Hurley Street Shares Outstanding 82 M
Price Hint 4 Target High Price 15.00 Website https://www.editasmedicine.com
52 Week Change -0.7911 Average Volume 2 M Forward Eps -2.35
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 366.60 %
Is_sp_500 False Regular Market Day High 2.28 Profit Margins 0.00 %
Debt To Equity 21.91 Fifty Two Week High 11.69 Day High 2.28
Shares Short 15 M Regular Market Open 2.23 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -0.7290 Revenue Growth -98.90 %
Shares Percent Shares Out 0.1927 Operating Cashflow -181762000 Currency USD
Time Zone Full Name America/New_York Market Cap 181 M Is_nasdaq_100 False
Zip 02141 Quote Type EQUITY Industry Biotechnology
Long Name Editas Medicine, Inc. Regular Market Day Low 2.18 Held Percent Institutions 0.7014
Current Price 2.20 Enterprise To Ebitda 0.2020 Financial Currency USD
Current Ratio 3.75 Gross Margins -256.53 % Industry Disp Biotechnology
Number Of Analyst Opinions 14 Country United States Float Shares 76 M
Two Hundred Day Average 5.11 Enterprise Value -44994184 Price To Sales Trailing12 Months 2.94
Forward PE -0.9543 Regular Market Volume 1 M Ebitda -222627008
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

It develops a proprietary gene editing platform based on CRISPR technology.

The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer.

It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.

Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.